| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 890 | 1,027 | 1,020 | 895 | 1,099 | 1,299 | 1,231 | 1,088 | 1,547 | 1,377 | 1,425 | 1,135 | 1,587 | 1,563 | 1,443 | 1,304 | 1,608 | 1,637 | 1,577 | 1,548 | 1,630 | 2,073 | 2,144 | 2,052 | 2,113 | 2,381 | 2,266 |
| Expenses | 757 | 838 | 772 | 716 | 881 | 1,019 | 942 | 908 | 947 | 1,003 | 1,045 | 886 | 1,152 | 1,184 | 1,123 | 1,070 | 1,317 | 1,341 | 1,330 | 1,331 | 1,278 | 1,713 | 1,722 | 1,848 | 1,700 | 1,913 | 1,782 |
| EBITDA | 133 | 188 | 247 | 179 | 218 | 279 | 289 | 180 | 599 | 374 | 380 | 249 | 435 | 378 | 320 | 234 | 291 | 296 | 247 | 217 | 353 | 360 | 422 | 204 | 413 | 468 | 483 |
| Operating Profit % | 14 % | 17 % | 23 % | 19 % | 18 % | 21 % | 22 % | 15 % | 38 % | 26 % | 26 % | 21 % | 26 % | 23 % | 22 % | 17 % | 17 % | 16 % | 14 % | 12 % | 19 % | 16 % | 16 % | 9 % | 19 % | 19 % | 21 % |
| Depreciation | 47 | 45 | 46 | 45 | 46 | 50 | 51 | 64 | 51 | 52 | 54 | 53 | 56 | 57 | 59 | 61 | 62 | 64 | 67 | 70 | 69 | 90 | 100 | 98 | 99 | 100 | 99 |
| Interest | 5 | 2 | 5 | 6 | 5 | 4 | 4 | 4 | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 3 | 7 | 9 | 11 | 19 | 31 | 44 | 33 | 29 | 24 | 23 | 17 |
| Profit Before Tax | 82 | 141 | 197 | 128 | 167 | 225 | 234 | 112 | 546 | 319 | 324 | 195 | 377 | 320 | 260 | 170 | 223 | 223 | 169 | 129 | 252 | 225 | 289 | 77 | 290 | 345 | 368 |
| Tax | 13 | 22 | 37 | 32 | 37 | 32 | 37 | 29 | 100 | 53 | 57 | 33 | 71 | 68 | 62 | 38 | 78 | 77 | 60 | 51 | 88 | 89 | 68 | 75 | 91 | 99 | 92 |
| Net Profit | 69 | 119 | 159 | 96 | 129 | 194 | 198 | 83 | 446 | 267 | 268 | 161 | 307 | 252 | 198 | 132 | 145 | 146 | 110 | 78 | 164 | 137 | 221 | 1 | 199 | 246 | 276 |
| EPS in ₹ | 5.43 | 9.38 | 12.59 | 7.60 | 10.24 | 15.32 | 15.63 | 6.57 | 35.27 | 21.11 | 21.09 | 12.71 | 24.18 | 19.73 | 7.76 | 5.13 | 5.64 | 5.67 | 4.25 | 3.02 | 6.42 | 5.72 | 7.09 | 2.35 | 7.58 | 9.05 | 9.78 |
IPCA Laboratories
1,446.75
-6.25
(-0.43%)
Market Cap
36,863.20 Cr
EPS
21.57
PE Ratio
46.40
Dividend Yield
0.28 %
Industry
Healthcare52 Week High
1,755.90
52 Week Low
1,052.00
PB Ratio
5.49
Debt to Equity
0.24
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from13 analysts
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
| 1,764.75 | 4,28,233.30 | 35.92 | 49,887.20 | 12.06 | 9,648 | 13.77 | 61.58 | |
| 5,840.65 | 1,56,910.50 | 74.97 | 8,184.00 | 0.89 | 1,600 | 64.53 | 55.23 | |
| 1,511.20 | 1,23,084.40 | 24.45 | 26,520.70 | 14.17 | 4,155 | 47.38 | 60.28 | |
| 3,245.05 | 1,10,720.70 | 58.75 | 10,785.70 | 11.59 | 1,656 | 13.54 | 61.68 | |
| 1,177.90 | 1,00,988.70 | 18.34 | 28,905.40 | 12.36 | 5,578 | 1.69 | 51.86 | |
| 2,398.05 | 97,867.10 | 48.47 | 10,615.60 | 19.57 | 1,942 | -16.38 | 56.07 | |
| 2,068.75 | 96,711.60 | 32.93 | 20,141.50 | 19.94 | 1,936 | 38.82 | 54.50 | |
| 907.35 | 92,945.80 | 20.14 | 19,831.50 | 13.82 | 3,831 | 29.92 | 48.54 | |
| 1,194.95 | 70,253.80 | 19.68 | 29,559.20 | 17.55 | 3,169 | -10.04 | 61.05 | |
| 31,101.85 | 66,026.50 | 49.49 | 6,097.20 | 10.80 | 1,201 | 16.01 | 61.04 |
Growth Rate
Revenue Growth
22.92 %
Net Income Growth
7.58 %
Cash Flow Change
17.23 %
ROE
-17.67 %
ROCE
-3.19 %
EBITDA Margin (Avg.)
11.80 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 3,812 | 3,892 | 3,960 | 4,117 | 4,551 | 5,260 | 6,068 | 7,624 | 8,626 | 11,101 |
| Fixed Assets | 1,800 | 2,014 | 1,983 | 1,953 | 1,940 | 2,059 | 2,072 | 2,402 | 2,751 | 4,553 |
| Current Assets | 1,614 | 1,622 | 1,742 | 1,946 | 2,378 | 2,856 | 3,437 | 4,447 | 5,189 | 5,539 |
| Capital Work in Progress | 267 | 129 | 95 | 73 | 66 | 133 | 235 | 306 | 140 | 343 |
| Investments | 0 | 26 | 136 | 87 | 120 | 310 | 505 | 989 | 626 | 862 |
| Other Assets | 1,745 | 1,723 | 1,746 | 2,005 | 2,424 | 2,758 | 3,256 | 3,926 | 5,109 | 5,343 |
| Total Liabilities | 3,812 | 3,892 | 3,960 | 4,117 | 4,551 | 5,260 | 6,068 | 7,624 | 8,626 | 11,101 |
| Current Liabilities | 904 | 970 | 956 | 1,008 | 1,098 | 1,326 | 1,161 | 1,466 | 1,806 | 2,356 |
| Non Current Liabilities | 700 | 663 | 548 | 421 | 315 | 292 | 192 | 616 | 905 | 1,019 |
| Total Equity | 2,208 | 2,259 | 2,455 | 2,689 | 3,138 | 3,641 | 4,716 | 5,542 | 5,915 | 7,727 |
| Reserve & Surplus | 2,183 | 2,234 | 2,430 | 2,663 | 3,097 | 3,590 | 4,676 | 5,440 | 5,817 | 6,307 |
| Share Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 29 | 29 | -26 | 75 | 153 | -76 | 264 | 432 | 588 | -823 |
| Investing Activities | -689 | -218 | -149 | -135 | -165 | -509 | -521 | -851 | -725 | -1,215 |
| Operating Activities | 468 | 709 | 282 | 341 | 501 | 570 | 1,090 | 856 | 806 | 945 |
| Financing Activities | 251 | -462 | -159 | -130 | -183 | -137 | -306 | 427 | 507 | -553 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 46.29 % | 46.29 % | 46.29 % | 46.29 % | 46.29 % | 46.29 % | 46.29 % | 46.29 % | 46.29 % | 46.29 % | 46.29 % | 46.29 % | 46.30 % | 46.30 % | 46.30 % | 44.72 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.02 % | 0.02 % | 0.02 % | 0.00 % | 9.86 % | 0.00 % | 10.51 % | 10.85 % | 10.83 % | 11.07 % |
| DIIs | 24.49 % | 24.86 % | 25.00 % | 29.73 % | 32.41 % | 33.31 % | 33.29 % | 34.03 % | 33.55 % | 35.19 % | 35.05 % | 33.79 % | 34.37 % | 33.78 % | 34.23 % | 35.68 % |
| Government | 0.28 % | 0.22 % | 0.22 % | 0.24 % | 0.24 % | 0.24 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 8.74 % | 8.25 % | 7.61 % | 7.75 % | 7.79 % | 7.50 % | 7.44 % | 7.41 % | 7.26 % | 6.98 % | 7.14 % | 7.12 % | 7.13 % | 7.27 % | 6.93 % | 6.88 % |
| Others | 20.20 % | 20.39 % | 20.89 % | 15.99 % | 13.27 % | 12.66 % | 12.97 % | 12.26 % | 12.89 % | 11.54 % | 1.67 % | 12.80 % | 1.69 % | 1.79 % | 1.71 % | 1.65 % |
| No of Share Holders | 1,00,626 | 1,05,428 | 95,239 | 1,06,779 | 1,15,335 | 1,10,818 | 1,11,043 | 1,08,177 | 1,10,296 | 99,889 | 95,930 | 82,809 | 81,165 | 84,753 | 82,975 | 90,189 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 1 | 1 | 3 | 5 | 8 | 4 | 4 | 4 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.31 | 0.2 | 0.43 | 0.53 | 0.75 | 0.51 | 0.32 | 0.28 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Announcement under Regulation 30 (LODR)-Change in Management
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Integrated Filing (Financial)
Standalone And Consolidated Q3FY25 Results
Board Meeting Outcome for Standalone And Consolidated Q3FY25 Results & Press Release
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Order Received Under CGST Act
Order Received Under Central Goods And Service Tax Act 2017
Orders Received Under CGST Act
Board Meeting Intimation for Standalone And Consolidated Unaudited Financial Results For Q3 And Nine Months Ended 31St December 2024
Order Received From Assistant Commissioner CGST Ratlam
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Change Of Name Of Registrar And Share Transfer Agent ("RTA") Of The Company
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
Voluntary Closure Of The Company''s Wholly Owned Subsidiary Ipca Pharmaceuticals Ltd SA De CV, Mexico
Announcement under Regulation 30 (LODR)-Newspaper Publication
Revision In Record Date For Entitlement Of Interim Dividend
Revision In Record Date For Entitlement Of Interim Dividend
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Corporate Action-Board approves Dividend
Unaudited Standalone And Consolidated Financial Results For Q2H1FY25
Board Meeting Outcome for Unaudited Standalone And Consolidated Financial Results For Q2H1FY25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Newspaper Publication
Revision In Record Date For Entitlement Of Interim Dividend
Revision In Record Date For Interim Dividend
Corporate Action-Board to consider Dividend
Record Date For Dividend
Board Meeting Intimation for Standalone And Consolidated Financial Results For 2Nd Quarter And Half Year Ended 30Th September, 2024 And Declaration Of Interim Dividend
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
To Enter Into Agreements By Bayshore Pharmaceuticals LLC, USA With Unichem Laboratories Limited And UnichemPharmaceuticals (USA) Inc So As To Integrate And Consolidate All The Ipca Group'S USA Generic Formulations Business Under One Entity
Board Meeting Outcome for To Enter Into Agreements By Bayshore Pharmaceuticals LLC, USA With Unichem Laboratories Limited And Unichem Pharmaceuticals (USA) Inc So As To Integrate And Consolidate All The Ipca Group'S USA Generic Formulations Business Under One Entity
Announcement under Regulation 30 (LODR)-Newspaper Publication
Board Meeting Intimation for Integration And Consolidation Of The Generics Formulations Business In The US Market
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Change in Directorate
Order Received From The Joint Commissioner (Appeals), CGST Jaipur Under Section 107 Of The CGST Act, 2017
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Approval Of Shareholders For Re-Appointment / Appointment Of Directors
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Announcement under Regulation 30 (LODR)-Newspaper Publication
Technical Indicators
RSI(14)
Neutral 58.10
ATR(14)
Volatile 50.74
STOCH(9,6)
Neutral 78.53
STOCH RSI(14)
Overbought 98.68
MACD(12,26)
Bullish 18.99
ADX(14)
Weak Trend 20.21
UO(9)
Bearish 61.72
ROC(12)
Uptrend But Slowing Down 6.21
WillR(14)
Overbought -16.00
About IPCA Laboratories
Ipca Laboratories Limited is an Indian integrated pharmaceutical company that manufactures and markets over 350 formulations and 80 active pharmaceutical ingredients (APIs) across various therapeutic segments. The company operates 18 manufacturing units in India and sells its products in over 100 countries worldwide. Ipca specializes in producing APIs such as Atenolol, Chloroquine Phosphate, Furosemide, and Pyrantel Salts. The company's facilities are approved by major drug regulatory authorities including the US FDA, UK MHRA, and others. Ipca has expanded through acquisitions and joint ventures, and has subsidiaries in various countries. The company focuses on research and development, and has recently acquired stakes in other pharmaceutical companies to strengthen its market position.
Website
Chairperson NamePremchand Godha
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
